AzTrials
AzTrials

Alzheimer's DiseasePhase 3MissionAD1NCT02956486

A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease

A Phase 3 study testing Elenbecestat in people with Alzheimer's Disease, run by Eisai Co., Ltd. at 258 sites in 18 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of E2609. Read more about this study

Who is it for?
Ages 50 to 85 years
Conditions the study is for
Alzheimer's Disease
What is being tested?
Elenbecestat
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
2,212 participants
Where
258 sitesin 18 countries
Study dates
20 Oct 2016to 15 Jan 2020
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Core Study
  • Mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia including
  • Mini Mental State Examination score equal to or greater than 24
  • Clinical Dementia Rating (CDR) global score of 0.5
  • CDR Memory Box score of 0.5 or greater
  • Impaired episodic memory confirmed by a list learning task
Show all 9Show fewer
  • Positive biomarker for brain amyloid pathology as indicated by either amyloid positron emission tomography or cerebrospinal fluid AD assessment or both
  • Extension Phase
  • Participants who complete the Core Study

Who cannot join

  • Core Study
  • Females who are breastfeeding or pregnant at Screening or Baseline. Females of child-bearing potential must use a highly effective method of contraception throughout the entire study period and for 28 days after study drug discontinuation
  • Any condition that may be contributing to cognitive impairment above and beyond that caused by the participant's AD
  • Participants with a history of seizures within 5 years of Screening
  • History of transient ischemic attacks or stroke within 12 months of Screening
  • Psychiatric diagnosis or symptoms (example, hallucinations, major depression, delusions etc.)
Show all 26Show fewer
  • Suicidal ideation or any suicidal behavior within 6 months before Screening or has been hospitalized or treated for suicidal behavior in the past 5 years
  • Have any contraindications to magnetic resonance imaging (MRI) scanning or
  • Have lesions that could indicate a dementia diagnosis other than AD on brain MRI
  • Exhibit other significant pathological findings on brain MRI.
  • Participants who have a history of moderate to severe hepatic impairment (example, Child-Pugh Class B or C)
  • Results of laboratory tests conducted during Screening that are outside the following limits:
  • Absolute lymphocyte count below the lower limit of normal (LLN)
  • Thyroid stimulating hormone above normal range
  • Abnormally low Vitamin B12 levels
  • Participants at increased risk of infection
  • Have received any live vaccine/live attenuated vaccine in the 3 months before randomization
  • Any chronic inflammatory disease that is not adequately controlled or that requires systemic immunosuppressive or immunomodulatory therapy
  • Any other clinically significant abnormalities
  • Severe visual or hearing impairment
  • A prolonged corrected QT (QTc) interval (QT interval with Fridericia's correction [QTcF] greater than 450 milliseconds [ms])
  • Malignant neoplasms within 5 years of Screening
  • Known or suspected history of drug or alcohol abuse
  • Taking prohibited medications, which must be reviewed with the Investigator
  • Have participated in a recent clinical study
  • Note: Other protocol-defined Inclusion/Exclusion Criteria may apply.

Trial locations and contacts

258 sites in 18 countries.

258 sites in 18 countries

United States88 sites
  • Facility #1

    Amherst, New York, 14226

  • Facility #1

    Atlanta, Georgia, 30328

  • Facility #1

    Atlantis, Florida, 33462

  • Facility #1

    Austin, Texas, 78757

  • Facility #1

    Aventura, Florida, 33187

  • Facility #2

    Aventura, Florida, 33187

  • Facility #1

    Bennington, Vermont, 5201

  • Facility #1

    Boston, Massachusetts, 2115

  • Facility #1

    Boynton Beach, Florida, 33437

  • Facility #1

    Brooklyn, New York, 11229

  • Facility #1

    Canton, Ohio, 44718

  • Facility #1

    Centerville, Ohio, 45459

  • Facility #1

    Chandler, Arizona, 85226

  • Facility #1

    Chesterfield, Missouri, 63005

  • Facility #1

    City of Saint Peters, Missouri, 63303

  • Facility #1

    Cleveland, Ohio, 44195

  • Facility #1

    Colton, California, 92324

  • Facility #1

    Columbus, Georgia, 31909

  • Facility #1

    Coral Gables, Florida, 33134

  • Facility #2

    Coral Gables, Florida, 33134

  • Facility #1

    Cordova, Tennessee, 38018

  • Facility #1

    Costa Mesa, California, 92626

  • Facility #1

    Dallas, Texas, 75231

  • Facility #1

    Dayton, Ohio, 45459

  • Facility #1

    Decatur, Georgia, 30033

  • Facility #1

    Delray Beach, Florida, 33445

  • Facility #1

    Denver, Colorado, 80218

  • Facility #1

    Doral, Florida, 33122

  • Facility #1

    East Providence, Rhode Island, 02914

  • Facility #1

    Farmington Hills, Michigan, 48334

  • Facility #1

    Fullerton, California, 92835

  • Facility #1

    Hampton, Virginia, 23666

  • Facility #1

    Hialeah, Florida, 33016

  • Facility #1

    Houston, Texas, 77084

  • Facility #1

    Imperial, California, 92251

  • Facility #1

    Irvine, California, 92618

  • Facility #1

    Jenkintown, Pennsylvania, 19046

  • Facility #1

    Lakewood, Ohio, 44107

  • Facility #1

    Lemon Grove, California, 91945

  • Facility #1

    Madison, Wisconsin, 53705

  • Facility #1

    Media, Pennsylvania, 19063

  • Facility #1

    Meridian, Idaho, 83642

  • Facility #2

    Miami, Florida, 33122

  • Facility #11

    Miami, Florida, 33125

  • Facility #9

    Miami, Florida, 33125

  • Facility #10

    Miami, Florida, 33126

  • Facility #4

    Miami, Florida, 33133

  • Facility #1

    Miami, Florida, 33137

  • Facility #6

    Miami, Florida, 33144

  • Facility #3

    Miami, Florida, 33155

  • Facility #7

    Miami, Florida, 33174

  • Facility #8

    Miami, Florida, 33176

  • Facility #1

    Mount Arlington, New Jersey, 7856

  • Facility #2

    Nashville, Tennessee, 37203

  • Facility #1

    Nashville, Tennessee, 37212

  • Facility #1

    New York, New York, 10032

  • Facility #1

    Northbrook, Illinois, 60062

  • Facility #1

    O'Fallon, Missouri, 63368

  • Facility #1

    Oceanside, California, 92054

  • Facility #2

    Oceanside, California, 92054

  • Facility #1

    Oklahoma City, Oklahoma, 73116

  • Facility #2

    Orlando, Florida, 32801

  • Facility #1

    Orlando, Florida, 32806

  • Facility #3

    Orlando, Florida, 32807

  • Facility #1

    Oxnard, California, 93030

  • Facility #1

    Palm Beach Gardens, Florida, 33410

  • Facility #1

    Panorama City, California, 91402

  • Facility #1

    Philadelphia, Pennsylvania, 19104

  • Facility #1

    Pompano Beach, Florida, 33064

  • Facility #1

    Port Charlotte, Florida, 33952

  • Facility #1

    Port Orange, Florida, 32127

  • Facility #1

    Port Royal, South Carolina, 29935

  • Facility #1

    Portland, Oregon, 97210

  • Facility #1

    Providence, Rhode Island, 2906

  • Facility #1

    Salt Lake City, Utah, 84108

  • Facility #1

    San Antonio, Texas, 78229-3900

  • Facility #3

    San Antonio, Texas, 78240

  • Facility #1

    San Diego, California, 92123

  • Facility #1

    Spring Hill, Florida, 34609

  • Facility #2

    Springfield, New Jersey, 7081

  • Facility #2

    St Louis, Missouri, 63104

  • Facility #1

    Suwanee, Georgia, 30024

  • Facility #1

    Tampa, Florida, 33613

  • Facility #2

    Tampa, Florida, 33614

  • Facility #1

    The Villages, Florida, 32162

  • Facility #1

    West Long Branch, New Jersey, 7764

  • Facility #1

    Westerville, Ohio, 43081

  • Facility #2

    Wichita, Kansas, 67214

Other trials in United States

Japan48 sites
  • Eisai Trial Site 1

    Anjo-shi, Aichi-ken, 446-8510

  • Eisai Trial Site 1

    Bunkyo-ku, Tokyo, 113-0034

  • Eisai Trial Site 2

    Bunkyo-ku, Tokyo, 113-8603

  • Eisai Trial Site 1

    Fujioka-shi, Gunma, 375-0017

  • Eisai Trial Site 1

    Fujisawa-shi, Kanagawa, 251-0038

  • Eisai Trial Site 1

    Higashimorokatagun, Miyazaki, 880-1111

  • Eisai Trial Site 1

    Himeji, Hyōgo, 671-1227

  • Eisai Trial Site 2

    Himeji-shi, Hyōgo, 670-0981

  • Facility #1

    Hiragi, Kagawa-ken, 761-0793

  • Eisai Trial Site 1

    Hirakata, Osaka, 573-1121

  • Eisai Trial Site 1

    Hofu-shi, Yamaguchi, 747-0802

  • Eisai Trial Site 1

    Kanzaki-gun, Saga-ken, 842-0192

  • Eisai Trail Site 1

    Kitakyushu-shi, Fukuoka, 808-0024

  • Eisai Trial Site 1

    Kobe, Hyōgo, 650-0017

  • Eisai Trial Site 1

    Kodaira-shi, Tokyo, 187-8551

  • Eisai Trial Site 1

    Kumamoto, 860-8556

  • Eisai Trial Site 1

    Kurashiki-shi, Okayama-ken, 710-0813

  • Eisai Trial Site 2

    Kurashiki-shi, Okayama-ken, 710-8692

  • Eisai Trial Site 1

    Kyoto, Kyoto, 602-8566

  • Eisai Trial Site 2

    Kyoto, Kyoto, 602-8566

  • Eisai Trial site 5

    Kyoto, Kyoto, 607-8113

  • Eisai Trial Site 4

    Kyoto, Kyoto, 616-8255

  • Eisai Trial Site 3

    Kyoto, 606-0851

  • Eisai Trial Site 1

    Minato-ku, Tokyo, 108-0073

  • Eisai Trial Site 1

    Nagoya, Aichi-ken, 467-8602

  • Eisai Trial Site 1

    Naniwa-Ku, Osaka, 556-0017

  • Eisai Trial Site 1

    Obu-shi, Aichi-ken, 474-8511

  • Eisai Trial Site 1

    Okayama, Okayama-ken, 700-8557

  • Eisai Trial Site 2

    Okayama, Okayama-ken, 701-1192

  • Eisai Trial Site 1

    Omuta-shi, Fukuoka, 837-0911

  • Eisai Trial Site 1

    Osaka, Osaka, 534-0021

  • Eisai Trial Site 3

    Osaka, Osaka, 543-8555

  • Eisai Trial Site 2

    Osaka, Osaka, 545-8586

  • Eisai Trial Site 1

    Osaka, 553-0003

  • Eisai Trial Site 1

    Otake-shi, Hiroshima, 739-0651

  • Eisai Trial Site 2

    Ōtsu, Shiga, 520-0832

  • Eisai Trial Site 1

    Ōtsu, Shiga, 520-2192

  • Eisai Trial site 2

    Sakai-shi, Osaka, 593-8301

  • Eisai Trial Site 1

    Setagaya-ku, Tokyo, 158-8531

  • Eisai Trial Site 1

    Shimogyo-ku, Kyoto, 600-8558

  • Eisai Trial Site 1

    Shinjuku-ku, Tokyo, 169-0073

  • Eisai Trial Site 1

    Suita-shi, Osaka, 565-0871

  • Eisai Trial Site 2

    Suita-shi, Osaka, 565-0874

  • Eisai Trial Site 1

    Sumida-ku, Tokyo, 130-0004

  • Eisai Trial Site 1

    Suminoe-ku, Osaka, 559-0004

  • Eisai Trial Site 3

    Takamatsu, Kagawa-ken, 760-8557

  • Eisai Trial Site 1

    Tokushima, Tokushima, 770-8503

  • Eisai Trial Site 1

    Yoshida-gun, Fukui, 910-1193

Other trials in Japan

United Kingdom24 sites
  • Facility #1

    Aberdeen, Scotland, AB25 2ZH

  • Facility #1

    Bath, North East Somerset, BA1 3NG

  • Facility #1

    Birmingham, West Midlands, B168QQ

  • Facility #1

    Blackpool, Lancashire, FY2 0JH

  • Facility #1

    Bournemouth, Dorset, BH1 4JQ

  • Facility #1

    Cambridge, Cambridgeshire, CB21 5EF

  • Facility #1

    Chester, Cheshire, CH2 1BQ

  • Facility #1

    Crowborough, East Sussex, TN6 1HB

  • Facility #1

    Glasgow, Lanarkshire, G20 0XA

  • Facility #2

    Glasgow, G51 4TF

  • Facility #1

    Guildford, GU2 7YD

  • Facility #1

    Leatherhead, Surrey, KT22 7AD

  • Facility #2

    London, Middlesex, TW7 6FY

  • Facility #1

    London, W1G 9RU

  • Facility #4

    London, W6 8RF

  • Facility #3

    London, WC1X 8QD

  • Facility #1

    Manchester, Greater Manchester, M13 9WL

  • Facility #1

    Oxford, Oxfordshire, OX3 7JX

  • Facility #1

    Plymouth, Devon, PL6 8BT

  • Facility #1

    Preston, Lancashire, PR2 8DW

  • Facility #1

    Sheffield, South Yorkshire, S5 7JT

  • Facility #1

    Southampton, Hampshire, SO30 3JB

  • Facility #1

    Swindon, Wilts, SN3 6BW

  • Facility #1

    Winwick, Warrington, Cheshire, WA2 8WA

Other trials in United Kingdom

Argentina14 sites
  • Facility #4

    Buenos Aires, 1199

  • Facility #2

    Caba, Buenos Aires, -1405

  • Facility #1

    Caba, Buenos Aires, C1012AAR

  • Facility #4

    Caba, Buenos Aires, C1126AAB

  • Facility #3

    Caba, Buenos Aires, C1427

  • Facility #5

    Caba, C1428AQK

  • Facility #1

    Ciudad Autonoma de Buenos Aires, Buenos Aires, 1111

  • Facility #3

    Ciudad Autonoma de Buenos Aires, Buenos Aires, 1430

  • Facility #2

    Ciudad Autonoma de Buenos Aires, Buenos Aires, C1230AAZ

  • Facility #1

    Córdoba, Capital, X5003DCE

  • Facility #2

    Córdoba, X5004A0A

  • Facility #3

    Córdoba, X5009BIN

  • Facility #1

    Rosario, Santa Fe Province, 2000

  • Facility #1

    Santa Fe, 3000

Other trials in Argentina

Australia12 sites
  • Facility #1

    Brisbane, Queensland, 4032

  • Facility #1

    Caulfield, Victoria, 3162

  • Facility #1

    Darlinghurst, New South Wales, 2010

  • Facility #1

    Geelong, Victoria, 3220

  • Facility #1

    Heidelberg, Victoria, 3084

  • Facility #1

    Macquarie Park, New South Wales, 2113

  • Facility #1

    Malvern, Victoria, 3144

  • Facility #2

    Melbourne, Victoria

  • Facility #3

    Melbourne, 3146

  • Facility #1

    Nedlands, Western Australia, 6009

  • Facility #1

    Parkville, Victoria, 3050

  • Facility #1

    Tumbi Vmbi, New South Wales, 2261

Other trials in Australia

Spain11 sites
  • Facility #1

    Barcelona, 8028

  • Facility #1

    Donostia / San Sebastian, Gipuzkoa, 20009

  • Facility #1

    El Palmar, Murcia, 30120

  • Facility #1

    Elche, Alicante, 3203

  • Facility #1

    Getxo, Bizkaia, 48993

  • Facility #2

    Madrid, 28049

  • Facility #1

    Madrid, 28223

  • Facility #1

    Palma de Mallorca, Balearic Islands, 7120

  • Facility #1

    Sant Cugat del Vallès, Barcelona, 8195

  • Facility #1

    Valencia, 46010

  • Facility #2

    Valencia, 46026

Other trials in Spain

Germany10 sites
  • Facility #1

    Berlin, 10245

  • Facility #2

    Berlin, 10629

  • Facility #1

    Frankfurt am Main, Hesse, 60528

  • Facility #1

    Gera, 7551

  • Facility #1

    Homburg/Saar, 66241

  • Facility #1

    Hoppegarten, Brandenburg, 15366

  • Facility #1

    Leipzig, Saxony, 4107

  • Facility #1

    Neuburg am Inn, Bavaria, 86633

  • Facility #1

    Oranienburg, Brandenburg, 16515

  • Facility #1

    Schwerin, 19053

Other trials in Germany

South Korea10 sites
  • Facility #1

    Bucheon-si, Gyeonggi-do, 14647

  • Facility #1

    Busan, 49201

  • Facility #1

    Incheon, 22332

  • Facility #1

    Seongnam-si, Gyeonggi-do, 13620

  • Facility #5

    Seoul, 3722

  • Facility #3

    Seoul, 4763

  • Facility #1

    Seoul, 5030

  • Facility #4

    Seoul, 6351

  • Facility #6

    Seoul, 6973

  • Facility #2

    Seoul, 7985

Other trials in South Korea

Canada9 sites
  • Facility #1

    Halifax, Nova Scotia, B3S 1M7

  • Facility #1

    Kamloops, British Columbia, V2C 5T1

  • Facility #1

    Kelowna, British Columbia, V1Y 1Z9

  • Facility #1

    Kentville, Nova Scotia, B4N 4K9

  • Facility #1

    Montreal, Quebec, H1M 1B1

  • Facility #1

    Ottawa, Ontario, K1N 5C8

  • Facility #1

    Peterborough, Ontario, K9H 2P4

  • Facility #1

    Sherbrooke, Quebec, J1L 0H8

  • Facility #1

    West Vancouver, British Columbia, V7T 1C5

Other trials in Canada

France8 sites
  • Facility #1

    Bordeaux, 33076

  • Facility #1

    Bron, 69677

  • Facility #1

    Marseille, 13385

  • Facility #1

    Montpellier, Herault, 34295

  • Facility #1

    Nantes, 44800

  • Facility #1

    Paris, 75013

  • Facility #1

    Rouen, 76000

  • Facility #1

    Toulouse, 31059

Other trials in France

Bulgaria7 sites
  • Facility #1

    Pleven, 5800

  • Facility #1

    Plovdiv, 4002

  • Facility #1

    Rousse, 7002

  • Facility #4

    Sofia, 1142

  • Facility #3

    Sofia, 1309

  • Facility #1

    Sofia, 1431

  • Facility #2

    Sofia, 1431

Other trials in Bulgaria

Poland7 sites
  • Facility #1

    Katowice

  • Facility #1

    Kielce, 25-411

  • Facility #1

    Krakow, 30-149

  • Facility #1

    Poznan

  • Facility #1

    Poznari, 61-853

  • Facility #1

    Siemianowice Śląskie, 41-100

  • Facility #1

    Warsaw, 01-684

Other trials in Poland

Czechia4 sites
  • Facility #1

    Hradec Králové, 500 09

  • Facility #1

    Kladno, 272 01

  • Facility #1

    Olomouc, 779 00

  • Facility #1

    Prague, 109 00

Other trials in Czechia

Greece2 sites
  • Facility #5

    Athens, 11528

  • Facility #4

    Athens, 15123

Other trials in Greece

Austria1 site
  • Facility #1

    Vienna, 1130

Other trials in Austria

Portugal1 site
  • Facility #1

    Guimarães, 4835-044

Other trials in Portugal

Russia1 site
  • Facility #1

    Moscow, 119991

Other trials in Russia

Slovakia1 site
  • Facility #1

    Bratislava, 85107

Other trials in Slovakia

About this study

Official title: A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease

The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of E2609. The Core is a 24-month treatment, multicenter, double blind, placebo controlled parallel group study. The OLE is a 24-month treatment, one group study. The data for the studies E2609-G000-301 (NCT02956486, MissionAD1) and E2609-G000-302 (NCT03036280, MissionAD2) will be pooled.

Being tested
Elenbecestat, Placebo
Keywords
Elenbecestat, E2609, Alzheimer's Disease, Early Alzheimer's Disease, Prodromal Alzheimer's Disease, Dementia, Dementia, Alzheimer's type, Mild Cognitive Impairment, MissionAD1
Medical subject headings
Alzheimer Disease, Dementia, Cognitive Dysfunction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ElenbecestatDrug

    Also called E2609

    Oral tablet.

  • PlaceboDrug

    Oral tablet.

Study groups in NCT02956486
Study groupRoleWhat they receive
Core Study: Elenbecestat 50 mgExperimentalParticipants will receive one 50 milligram (mg) elenbecestat tablet, orally, once a day in the morning. The core study will be double blinded.
Receives: Drug: Elenbecestat
Core Study: PlaceboPlacebo comparatorParticipants will receive one matching placebo tablet, orally, once a day in the morning. The core study will be double blinded.
Receives: Drug: Placebo
Open-label Extension Phase: Elenbecestat 50 mgExperimentalParticipants completing the core study will receive one 50 mg elenbecestat tablet, orally, once a day in the morning.
Receives: Drug: Elenbecestat

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Core Phase: Change From Baseline up to Month 24 in the Clinical Dementia Rating-sum of Boxes (CDR-SB) Score

    The clinical dementia rating (CDR) scale is a clinical global rating scale that requires interviewing both the participant and an informant who knows and has contact with the participant. The CDR scale is a clinician directed assessment of both cognition and function, and is intended to capture the state and therefore the disease stage of the participant. The CDR scale assesses 6 domains of participant function (memory, orientation, judgement and problem solving, community affairs, home and hobbies and personal care) on a 5-point scale in which no impairment=0, questionable impairment=0.5, mild impairment=1, moderate impairment=2 and severe impairment=3. The CDR-SB is a sum of the individual domain scores and ranges from 0 to 18. Higher score indicates more impairment.

    Measured: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase

  2. Extension Phase: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)

    A TEAE is defined as an adverse event that emerged during treatment or within 28 days following the last dose of study drug, having been absent at pretreatment (Baseline) or reemerged during treatment, having been present at pretreatment (Baseline) but stopped before treatment, or worsened in severity during treatment relative to the pretreatment state, when the adverse event was continuous. Number of participants with TEAEs (serious and non-serious adverse events) were reported based on their safety assessments of laboratory tests, suicidal ideation and suicidal behavior, drug abuse potential, physical examination, neurological examination, regular measurement of vital signs, magnetic resonance imaging and electrocardiogram parameter values.

    Measured: From first dose of study drug up to approximately 6 months (including 1 month follow up) for the extension phase

Secondary outcomes (25)
  1. Core Phase: Change From Baseline up to Month 24 in Alzheimer's Disease Composite Score (ADCOMS)

    ADCOMS is a weighted linear combination of 12 items from three existing clinical scales: the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), the Mini Mental State Examination (MMSE), and the CDR. Four items are from the ADAS-cog (A4 [Delayed Word Recall], A7 [Orientation], A8 [Word Recognition], A11 [Word Finding]); 2 items are from the MMSE (M1 [Orientation Time], M7 [Drawing]); 6 items are from the CDR (C1 [Personal Care], C2 [Community Affairs], C3 [Home and Hobbies], C4 [Judgment and Problem Solving], C5 [Memory], C6 [Orientation]). Composite score is derived from the variables from the 12 items, and ranges from 0 to 1.97, where higher score indicates worse performance.

    Measured: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase

  2. Core Phase: Change From Baseline up to Month 24 in Amyloid Positron Emission Tomography (PET) Standardized Uptake Value Ratio (SUVR)

    Amyloid PET scan assesses cerebral amyloid load using 3 tracers (florbetapir, florbetaben and flutemetamol) which is standardized into centiloids for evaluation of AD. Centiloid values on centiloid scale is based on mean composite SUVR in cingulate, frontal, parietal and temporal cortexes using whole cerebellum as reference region. SUVR is ratio of tracer uptake in each of cingulate, frontal, parietal and temporal cortexes relative to cerebellum. The centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scans.

    Measured: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase

  3. Core Phase: Change From Baseline up to Month 24 in the CDR-SB Score for Participants Enriched by Baseline Amyloid PET SUVR Between 1.2 and 1.6

    The CDR scale is a clinical global rating scale that requires interviewing both the participant and an informant who knows and has contact with the participant. The CDR scale is a clinician directed assessment of both cognition and function, and is intended to capture the state and therefore the disease stage of the participant. The CDR scale assesses 6 domains of participant function (memory, orientation, judgement and problem solving, community affairs, home and hobbies and personal care) on a 5-point scale in which no impairment=0, questionable impairment=0.5, mild impairment=1, moderate impairment=2 and severe impairment=3. The CDR-SB is a sum of the individual domain scores and ranges from 0 to 18. Higher score indicates more impairment. Amyloid PET scans allow in vivo assessment of cerebral amyloid load. SUVR indicates the ratio of tracer uptake in the frontal cortex relative to the cerebellum or the ratio of tracer uptake in the whole brain relative to the cerebellum.

    Measured: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase

  4. Core Phase: Change From Baseline up to Month 24 in the ADCOMS for Participants Enriched by Baseline Amyloid PET SUVR Between 1.2 and 1.6

    ADCOMS is a weighted linear combination of 12 items from three existing clinical scales: the ADAS-cog, the MMSE, and the CDR. Four items are from the ADAS-cog (A4 [Delayed Word Recall], A7 [Orientation], A8 [Word Recognition], A11 [Word Finding]); 2 items are from the MMSE (M1 [Orientation Time], M7 [Drawing]); 6 items are from the CDR (C1 [Personal Care], C2 [Community Affairs], C3 [Home and Hobbies], C4 [Judgment and Problem Solving], C5 [Memory], C6 [Orientation]). Composite score is derived from the variables from the 12 items, and ranges from 0 to 1.97, where higher score indicates worse performance. Amyloid PET scans allow in vivo assessment of cerebral amyloid load. SUVR indicates the ratio of tracer uptake in the frontal cortex relative to the cerebellum or the ratio of tracer uptake in the whole brain relative to the cerebellum.

    Measured: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase

  5. Core Phase: Change Per Year (Mean Slope) in CDR-SB Score up to Month 24

    The CDR scale is a clinical global rating scale that requires interviewing both the participant and an informant who knows and has contact with the participant. The CDR scale is a clinician directed assessment of both cognition and function, and is intended to capture the state and therefore the disease stage of the participant. The CDR scale assesses 6 domains of participant function (memory, orientation, judgement and problem solving, community affairs, home and hobbies and personal care) on a 5-point scale in which no impairment=0, questionable impairment=0.5, mild impairment=1, moderate impairment=2 and severe impairment=3. The CDR-SB is a sum of the individual domain scores and ranges from 0 to 18. Higher score indicates more impairment. In this outcome measure, change per year (mean slope) in CDR-SB score was calculated up to month 24, where higher change indicated more impairment and lower change indicated less impairment.

    Measured: Up to Month 24 of the core phase

  6. Core Phase: Time to Worsening of CDR Score up to Month 24

    The CDR scale is a clinical global rating scale that requires interviewing both the participant and an informant who knows and has contact with the participant. The CDR scale is a clinician directed assessment of both cognition and function, and is intended to capture the state and therefore the disease stage of the participant. The CDR scale assesses 6 domains of participant function (memory, orientation, judgement and problem solving, community affairs, home and hobbies and personal care) on a 5-point scale in which no impairment=0, questionable impairment=0.5, mild impairment=1, moderate impairment=2 and severe impairment=3. The global CDR score is computed via an algorithm and ranges from 0 to 3. Higher score indicates more impairment. In this outcome measure, time (in months) to worsening of CDR score (that is, an increase from baseline by at least 0.5 points on the global CDR scale on 2 consecutive scheduled visits) up to month 24 was calculated.

    Measured: Up to Month 24 of the core phase

  7. Core Phase: Time to Conversion to Dementia for Participants Who Were Not Clinically Staged as Having Dementia at the Core Phase Baseline up to Month 24

    Time (in months) to conversion to dementia for participants who were not clinically staged as having dementia at the core phase baseline (that is time from randomization to conversion to dementia in clinical diagnosis).

    Measured: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase

  8. Core Phase: Change From Baseline up to Month 24 in the Alzheimer's Disease Assessment Scale-cognition14 (ADAS-Cog14) Score

    ADAS-cog14 is a psychometric instrument that evaluates 14-items (Immediate Word-recall [0-10], Commands [0-5], Constructional Praxis [0-5], Delayed Word-recall [0-10], Naming Objects/Fingers [0-5], Ideational Praxis [0-5], Orientation[0-8], Word Recognition [0-12], Remembering Test Instructions [0-5], Comprehension[0-5], Word Finding Difficulty [0-5], Spoken Language Ability [0-5], Executive Function [0-5], and Number Cancellation [0-5] test). It is considered to be more sensitive for less impaired populations such as MCI/Prodromal and mild AD participants. The total score ranges from 0 to 90. Higher score indicates more impairment.

    Measured: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase

  9. Core Phase: Change From Baseline up to Month 24 in the MMSE Score

    The MMSE is a cognitive instrument commonly used for screening purposes, for staging of disease severity and is often measured longitudinally in AD clinical studies to follow disease progression and treatment effects. MMSE is composed of 30 questions grouped into domains (Orientation to Time [0-5], Orientation to Place [0-5], Registration [0-3], Attention and Calculation [0-5], Recall [0-3], Naming [0-2], Repetition [0-1], Comprehension [0-3], Reading [0-1], Writing [0-1], Drawing [0-1]). For each of the MMSE domains, six items are computed (Orientation to Time [0-5], Orientation to Place [0-5], Registration [0-3], Attention and Calculation [0-5], Recall [0-3], Language: Naming, Repetition, Comprehension, Reading, Writing, and Drawing [0-9]). The MMSE Total Score is the sum of the six domains and ranges from 0 to 30. If any domain score was missing then the total score was missing. Higher score indicates better function.

    Measured: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase

  10. Core Phase: Change From Baseline up to Month 24 in the Functional Assessment Questionnaire (FAQ) Score

    FAQ scores 10 items \& measures activities of daily living (paying bills/balancing checkbook, assembling tax records, shopping alone for clothes or groceries, playing game of skill such as bridge or chess/working on a hobby, heating water \& turning off stove, preparing balanced meal, keeping track of current events, paying attention \& understanding television program, remembering appointments, driving or traveling out of neighborhood). Each item is rated as follows: 0=Normal, 1=Has difficulty but does by self, 2=Requires assistance, 3=Dependent, or 8=Not Applicable. The total score is the sum of all 10 items \& ranges from 0 to 30. Higher score indicates more impairment. If any activity was missed, then the total score was missed. Activities rated as "Not Applicable" were not used in the computation of the total score. To account for "Not Applicable" activity, the total score was weighted as:Total Score=Total Score*30/(30 minus 3 times the number of activities marked"Not Applicable").

    Measured: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase

  11. Core Phase: Change From Baseline up to Month 24 in the ADAS-cog14 Word List (Immediate Recall and Delayed Recall) Score

    The ADAS-cog14 Word List is a summation of two items: "Immediate Word-recall" and "Delayed Word-recall". Immediate Word-recall test: Participants are asked to recall words and the number of "No" responses for each trial (total 3 trials) are summed. Subscore: sum of scores from 3 trials, divided by 3. Score ranges from 0 to 10. Delayed Word-recall: Participants used to recall words after a delay and the number of "No" responses are summed. Score ranges from 0 to 10. The Total Score ranges from 0 to 20. Higher score indicates more impairment.

    Measured: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase

  12. Core Phase: Change From Baseline up to Month 24 in the Alzheimer's Disease Assessment Scale-cognition11 (ADAS-Cog11) Score

    ADAS-cog11 is a psychometric instrument that evaluates 11-items (Immediate Word-recall [0 to 10], Commands [0-5], Constructional Praxis [0-5], Naming Objects/Fingers [0-5], Ideational Praxis [0-5], Orientation[0-8], Word Recognition [0-12], Remembering Test Instructions [0-5], Comprehension[0-5], Word Finding Difficulty [0-5], Spoken Language Ability [0-5] test) and is considered more sensitive for less impaired populations such as MCI/Prodromal and mild AD participants. The Total score ranges from 0 to 70. Higher score indicates more impairment.

    Measured: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase

  13. Core Phase: Change From Last Dose in the CDR-SB Score

    The CDR scale is a clinical global rating scale that requires interviewing both the participant and an informant who knows and has contact with the participant. The CDR scale is a clinician directed assessment of both cognition and function, and is intended to capture the state and therefore the disease stage of the participant. The CDR scale assesses 6 domains of participant function (memory, orientation, judgement and problem solving, community affairs, home and hobbies and personal care) on a 5-point scale in which no impairment=0, questionable impairment=0.5, mild impairment=1, moderate impairment=2 and severe impairment=3. The CDR-SB is a sum of the individual domain scores and ranges from 0 to 18. Higher score indicates more impairment.

    Measured: From last dose in the core phase (up to Month 24) up to 3 months follow up (up to Month 27)

  14. Core Phase: Change From Last Dose in the ADCOMS

    ADCOMS is a weighted linear combination of 12 items from three existing clinical scales: the ADAS-cog, the MMSE, and the CDR. Four items are from the ADAS-cog (A4 [Delayed Word Recall], A7 [Orientation], A8 [Word Recognition], A11 [Word Finding]); 2 items are from the MMSE (M1 [Orientation Time], M7 [Drawing]); 6 items are from the CDR (C1 [Personal Care], C2 [Community Affairs], C3 [Home and Hobbies], C4 [Judgment and Problem Solving], C5 [Memory], C6 [Orientation]). Composite score is derived from the variables from the 12 items, and ranges from 0 to 1.97, where higher score indicates worse performance.

    Measured: From last dose in the core phase (up to Month 24) up to 3 months follow-up (up to Month 27)

  15. Core Phase: Change From Last Dose in the ADAS-cog11 Score

    ADAS-cog11 is a psychometric instrument that evaluates 11-items (Immediate Word-recall [0 to 10], Commands [0-5], Constructional Praxis [0-5], Naming Objects/Fingers [0-5], Ideational Praxis [0-5], Orientation[0-8], Word Recognition [0-12], Remembering Test Instructions [0-5], Comprehension[0-5], Word Finding Difficulty [0-5], Spoken Language Ability [0-5] test) and is considered more sensitive for less impaired populations such as MCI/Prodromal and mild AD participants. The Total score ranges from 0 to 70. Higher score indicates more impairment.

    Measured: From last dose in the core phase (up to Month 24) up to 3 months follow-up (up to Month 27)

  16. Core Phase: Change From Last Dose in the ADAS-cog14 Score

    ADAS-cog14 is a psychometric instrument that evaluates 14-items (Immediate Word-recall [0 to 10], Commands [0-5], Constructional Praxis [0-5], Delayed Word-recall [0-10], Naming Objects/Fingers [0-5], Ideational Praxis [0-5], Orientation[0-8], Word Recognition [0-12], Remembering Test Instructions [0-5], Comprehension[0-5], Word Finding Difficulty [0-5], Spoken Language Ability [0-5], Executive Function [0-5], and Number Cancellation [0-5] test). It is considered to be more sensitive for less impaired populations such as MCI/Prodromal and mild AD participants. The Total Score ranges from 0 to 90. Higher score indicates more impairment.

    Measured: From last dose in the core phase (up to Month 24) up to 3 months follow-up (up to Month 27)

  17. Core Phase: Change From Last Dose in the MMSE Score

    The MMSE is a cognitive instrument commonly used for screening purposes, for staging of disease severity and is often measured longitudinally in AD clinical studies to follow disease progression and treatment effects. MMSE is composed of 30 questions grouped into domains (Orientation to Time [0-5], Orientation to Place [0-5], Registration [0-3], Attention and Calculation [0-5], Recall [0-3], Naming [0-2], Repetition [0-1], Comprehension [0-3], Reading [0-1], Writing [0-1], Drawing [0-1]). For each of the MMSE domains, six items are computed (Orientation to Time [0-5], Orientation to Place [0-5], Registration [0-3], Attention and Calculation [0-5], Recall [0-3], Language: Naming, Repetition, Comprehension, Reading, Writing, and Drawing [0-9]). The MMSE Total Score is the sum of the six domains and ranges from 0 to 30. If any domain score was missing then the total score was missing. Higher score indicates better function.

    Measured: From last dose in the core phase (up to Month 24) up to 3 months follow-up (up to Month 27)

  18. Core Phase: Change From Last Dose in the ADAS-cog14 Word List (Immediate Recall and Delayed Recall) Score

    The ADAS-cog14 Word List is a summation of two items: "Immediate Word-recall" and "Delayed Word-recall". Immediate Word-recall test: Participants are asked to recall words and the number of "No" responses for each trial (total 3 trials) are summed. Subscore: sum of scores from 3 trials, divided by 3. Score ranges from 0 to 10. Delayed Word-recall: Participants used to recall words after a delay and the number of "No" responses are summed. Score ranges from 0 to 10. The Total Score ranges from 0 to 20. Higher score indicates more impairment.

    Measured: From last dose in the core phase (up to Month 24) up to 3 months follow-up (up to Month 27)

  19. Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in CDR-SB Score

    The CDR scale is a clinical global rating scale that requires interviewing both the participant and an informant who knows and has contact with the participant. The CDR scale is a clinician directed assessment of both cognition and function, and is intended to capture the state and therefore the disease stage of the participant. The CDR scale assesses 6 domains of participant function (memory, orientation, judgement and problem solving, community affairs, home and hobbies and personal care) on a 5-point scale in which no impairment=0, questionable impairment=0.5, mild impairment=1, moderate impairment=2 and severe impairment=3. The CDR-SB is a sum of the individual domain scores and ranges from 0 to 18. Higher score indicates more impairment.

    Measured: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase

  20. Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in ADCOMS

    ADCOMS is a weighted linear combination of 12 items from three existing clinical scales: the ADAS-cog, the MMSE, and the CDR. Four items are from the ADAS-cog (A4 [Delayed Word Recall], A7 [Orientation], A8 [Word Recognition], A11 [Word Finding]); 2 items are from the MMSE (M1 [Orientation Time], M7 [Drawing]); 6 items are from the CDR (C1 [Personal Care], C2 [Community Affairs], C3 [Home and Hobbies], C4 [Judgment and Problem Solving], C5 [Memory], C6 [Orientation]). Composite score is derived from the variables from the 12 items, and ranges from 0 to 1.97, where higher score indicates worse performance.

    Measured: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase

  21. Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in MMSE Score

    The MMSE is a cognitive instrument commonly used for screening purposes, for staging of disease severity and is often measured longitudinally in AD clinical studies to follow disease progression and treatment effects. MMSE is composed of 30 questions grouped into domains (Orientation to Time [0-5], Orientation to Place [0-5], Registration [0-3], Attention and Calculation [0-5], Recall [0-3], Naming [0-2], Repetition [0-1], Comprehension [0-3], Reading [0-1], Writing [0-1], Drawing [0-1]). For each of the MMSE domains, six items are computed (Orientation to Time [0-5], Orientation to Place [0-5], Registration [0-3], Attention and Calculation [0-5], Recall [0-3], Language: Naming, Repetition, Comprehension, Reading, Writing, and Drawing [0-9]). The MMSE Total Score is the sum of the six domains and ranges from 0 to 30. If any domain score is missing then the total score is missing. Higher score indicates better function.

    Measured: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase

  22. Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in FAQ Score

    FAQ scores 10 items \& measures activities of daily living (paying bills/balancing checkbook, assembling tax records, shopping alone for clothes or groceries, playing game of skill such as bridge or chess/working on a hobby, heating water \& turning off stove, preparing balanced meal, keeping track of current events, paying attention \& understanding television program, remembering appointments, driving or traveling out of neighborhood). Each item is rated as follows: 0=Normal, 1=Has difficulty but does by self, 2=Requires assistance, 3=Dependent, or 8=Not Applicable. The total score is the sum of all 10 items \& ranges from 0 to 30. Higher score indicates more impairment. If any activity was missed, then the total score was missed. Activities rated as "Not Applicable" were not used in the computation of the total score. To account for "Not Applicable" activity, the total score was weighted as:Total Score=Total Score*30/(30 minus 3 times the number of activities marked"Not Applicable").

    Measured: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase

  23. Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in ADAS-cog14 Score

    ADAS-cog14 is a psychometric instrument that evaluates 14-items (Immediate Word-recall [0 to 10], Commands [0-5], Constructional Praxis [0-5], Delayed Word-recall [0-10], Naming Objects/Fingers [0-5], Ideational Praxis [0-5], Orientation[0-8], Word Recognition [0-12], Remembering Test Instructions [0-5], Comprehension[0-5], Word Finding Difficulty [0-5], Spoken Language Ability [0-5], Executive Function [0-5], and Number Cancellation [0-5] test). It is considered to be more sensitive for less impaired populations such as MCI/Prodromal and mild AD participants. The total score ranges from 0 to 90. Higher score indicates more impairment.

    Measured: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase

  24. Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in ADAS-cog14 Word List (Immediate Recall and Delayed Recall) Score

    The ADAS-cog14 Word List is a summation of two items: "Immediate Word-recall" and "Delayed Word-recall". Immediate Word-recall test: Participants are asked to recall words and the number of "No" responses for each trial (total 3 trials) are summed. Subscore: sum of scores from 3 trials, divided by 3. Score ranges from 0 to 10. Delayed Word-recall: Participants used to recall words after a delay and the number of "No" responses are summed. Score ranges from 0 to 10. The Total Score ranges from 0 to 20. Higher score indicates more impairment.

    Measured: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase

  25. Extension Phase: Time to Conversion to Dementia for Participants Who Were Not Clinically Staged as Having Dementia at the Core Phase Baseline up to Month 12 of the Extension Phase

    Time (in months) to conversion to dementia for participants who were not clinically staged as having dementia at the core phase baseline (that is time from randomization to conversion to dementia in clinical diagnosis).

    Measured: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Nov 2016 (estimated)
  2. Study start20 Oct 2016
  3. Primary completion15 Jan 2020
  4. Study completion15 Jan 2020

Why it stopped: Due to an unfavorable risk-benefit ratio including no evidence of potential efficacy, and the adverse event profile of E2609 being worse than placebo.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
2,212 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02956486
Sponsor's protocol ID
E2609-G000-301
Other IDs
2016-003928-23, 2016-004128-42, 2016
Acronym
MissionAD1
Status last verified
Jan 2021
First submitted
3 Nov 2016
Last updated
3 Feb 2021
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Devanarayan V, Doherty T, Charil A, Sachdev P, Ye Y, Murali LK, Llano DA, Zhou J, Reyderman L, Hampel H, Kramer LD, Dhadda S, Irizarry MC. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease. Alzheimers Dement. 2024 Aug;20(8):5617-5628. doi: 10.1002/alz.14073. Epub 2024 Jun 28.

    PubMed 38940656
  • Devanarayan V, Ye Y, Charil A, Andreozzi E, Sachdev P, Llano DA, Tian L, Zhu L, Hampel H, Kramer L, Dhadda S, Irizarry M; Alzheimer's Disease Neuroimaging Initiative (ADNI). Predicting clinical progression trajectories of early Alzheimer's disease patients. Alzheimers Dement. 2024 Mar;20(3):1725-1738. doi: 10.1002/alz.13565. Epub 2023 Dec 13.

    PubMed 38087949
  • Bullich S, Mueller A, De Santi S, Koglin N, Krause S, Kaplow J, Kanekiyo M, Roe-Vellve N, Perrotin A, Jovalekic A, Scott D, Gee M, Stephens A, Irizarry M. Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects-a MissionAD tau sub-study. Alzheimers Res Ther. 2022 Jul 27;14(1):105. doi: 10.1186/s13195-022-01048-x.

    PubMed 35897078

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Elenbecestat in people with Alzheimer's Disease, run by Eisai Co., Ltd. at 258 sites in 18 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 3 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 258 sites in United States, Japan, United Kingdom, Argentina, Australia and 13 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 3 Feb 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Core Phase: Change From Baseline up to Month 24 in the Clinical Dementia Rating-sum of Boxes (CDR-SB) Score (time frame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02956486, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Feb 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in